-
Inadequate and inconsistent
#PatientAccess to#orphanmedicines in the UK because of the@NICEcomms appraisal process is not 'new' news, but this report brings together the evidence rather compellingly https://mapbiopharma.com/2019/02/new-report-from-map-biopharma-on-access-to-orphan-medicines/ …@MAPBioPharma@rarediseaseuk @ataxiaandme -
Register with http://bepharma.org or contact us at contacto@bepharma.org
#licensing#partnering#nicheproducts#orphanmedicines#generics#OTC#supplements#medicaldevices#dermocosmetics#foodsupplements#probiotics#nanotechnology#BePharma#BePharmaMexico#B2BEventspic.twitter.com/zS6eqCufT3 -
Read here as
@SidleyLaw's@MarieManley3 and Chris Boyle discuss the current EU legal framework for#orphanmedicines and the impact of regulatory frameworks on medicines for rare diseases. Via@Pharmafocus https://bit.ly/2sfY6TC pic.twitter.com/3cNfFK0HOn
-
Pick up your copy of the
#OrphanMedicines white paper, available today at the IQVIA Biotech booth 80 at#bioeuropespring@EBDgroup http://bit.ly/2U7T4oO pic.twitter.com/cVg2yZ376q
-
Pick up a copy of our Access to
#OrphanMedicines report on our stand at#ISPOREurope 2019!@ISPORorg Find out more on MAP Online: https://bit.ly/2JCWv00#rarediseases#marketaccess#patientaccesspic.twitter.com/11ObCgiim0
-
Today we are meeting EU healthcare payers in Diemen
to discuss evidence generation for #OrphanMedicines, unmet medical needs & horizon scanning for#medicines. Our close collaboration is key for timely & affordable access for#patients to new
https://www.ema.europa.eu/en/events/european-medicines-agency-ema-european-union-eu-payer-community-meeting …pic.twitter.com/1jzpWyLJYm
-
Very happy to share with you an article co-authored with colleagues in the industry on
#orphanmedicines for#pediatric use in the#EU published in#ClinicalTherapeutics https://sciencedirect.com/science/article/pii/S0149291819305028 …#orphan#raredisease#children#regulatory#regulatoryscience -
#OrphanMedicines face market access challenges & patient insight & access needs.They require patient-centric approaches & need to fulfill all Launch Excellence requirements.Find out how#Raredisease companies are addressing these challenges. http://bit.ly/2JHBwuM@pharmaphorumpic.twitter.com/2nW4wvvugT
-
We thank Terumo for sponsoring
#BePharmaMexico2020 Register with http://bepharma.org#licensing#partnering#nicheproducts#orphanmedicines#generics#OTC#supplements#medicaldevices#herbalmedicines#homeopathy#dermocosmetics#foodsupplements#probiotics#nanotechnologypic.twitter.com/wDQyvl5mZG
-
#BePharma Mexico is the most important pharmaceutical B2B event in america where you can promote your products and services on one-on-one business meetings. Go to http://bepharma.org for more info and registration!!#licensing#partnering#nicheproducts#orphanmedicines pic.twitter.com/7m3jbErL8U -
We welcome Galenicum Health as new particpant of
#BePharmaMexico2020 Register with http://bepharma.org#licensing#partnering#nicheproducts#orphanmedicines#generics#dermocosmetics#foodsupplements#probiotics#nanotechnology#BePharma#BePharmaMexico#B2BEventspic.twitter.com/cEyY9cXyVi
-
In BePharma 2020, you will have the opportunity to confirm up to 40 face-to-face meetings during the three days of the event. Register today with http://bepharma.org
#licensing#partnering#nicheproducts#orphanmedicines#generics#OTC#supplements#medicaldevicespic.twitter.com/SmJzVTgF4u
-
Did you know 95% of
#RareDiseases have no approved medicinal treatment? Read@TakedaPharma’s Rute Fernandes to understand how the#OrphanMedicines Regulation and other initiatives can better patients’ lives. http://bit.ly/2J7brn5 -
Launching orphan medicines comes with unique
#raredisease challenges. Find out how to sustain launch success of#orphanmedicines as they come of age with#IQVIA’s Sarah Rickwood in Spain at the World Orphan Drug Congress: http://bit.ly/31IX0vQ#TotalOrphanDrugs pic.twitter.com/W1GYxYNbD5
-
“At least 95% of rare diseases do not have any approved medicinal treatment,” explains Rute Fernandes, Head of
#RareDiseases for#Europe and Canada@TakedaPharma, on how the#OrphanMedicines Regulation and other initiatives can better patients’ lives. http://bit.ly/2J7brn5 pic.twitter.com/k7TaA4iHGP
-
Huge strides have been made to tackle
#RareDiseases, notably thanks to the#OrphanMedicines Regulation. Yet there is still a lot of work to be done. We invited@TakedaPharma,@eurordis,@RareEndoERN and@EU_Health to identify the best ways forward. http://bit.ly/2Y4wDPe pic.twitter.com/GQBWJcUcZm
-
As innovations for rare diseases develop, we examine what considerations are needed for a successful orphan medicine launch. Find out more: http://bit.ly/2Z8ydjA
#IQVIABiotech#OrphanMedicines pic.twitter.com/rVLYZoEi39
-
FDA’s Center for Biologics Evaluation and Research (CBER) plans draft guidance on ‘sameness’ of gene therapies under orphan drug regulations
#regulation#orphanmedicines - http://ow.ly/siRv50vw1Nb pic.twitter.com/AvJ3CwQY0n
-
You can now read a roundup of our latest webinar, where experts from
@IQVIA_global discussed ways that#pharma companies can ensure#orphanmedicines have successful launches http://bit.ly/2S1R79E#launchexcellence -
Missed our
#orphanmedicines webinar with@IQVIA_global last week? You can still view it on demand http://bit.ly/30bRMJA#launchexcellence#rarediseasespic.twitter.com/EggeivMgiQ
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.